Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Male
  • Multiple Myeloma / drug therapy*
  • Neoplasm Recurrence, Local / drug therapy*
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Bortezomib
  • Dexamethasone